Versartis Inc (VSAR) Drops 6.04% on February 03

Equities Staff |

Versartis Inc (VSAR) was one of the Russell 2000's biggest losers for Wednesday February 03 as the stock slid 6.04% to $9.49, a loss of $-0.61 per share. Starting at an opening price of $10.15 a share, the stock traded between $9.32 and $10.55 over the course of the trading day. Volume was 175,865 shares over 1,615 trades, against an average daily volume of 153,812 shares and a total float of 29.36 million.

The losses send Versartis Inc down to a market cap of $278.63 million. In the last year, Versartis Inc has traded between $22.66 and $8.97, and its 50-day SMA is currently $11.66 and 200-day SMA is $13.98.

Versartis Inc is a development stage biopharmaceutical company developing therapeutic proteins for the treatment of metabolic diseases and endocrine disorders.

Versartis Inc is based out of Menlo Park, CA and has some 44 employees. Its CEO is Jay P. Shepard.

For a complete fundamental analysis analysis of Versartis Inc, check out Equities.com’s Stock Valuation Analysis report for VSAR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and…

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…

California Green Tree Development

California Green Tree Development LLC (CGTD) is a for-profit LLC that plans on using California’s booming market of legal cannabis products for medical purposes. As an unprecedented resource, Cannabis has…